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SIROLIMUS AND TACROLIMUS WITHOUT METHOTREXATE TO PRE- 
VENT GRAFT-VS-HOST DISEASE AFTER MATCHED, RELATED STEM 
CELL TRANSPLANTATION 
Cz~tler, C.; Ho, V.; Alyea, E.; Lee, S.J.; Soiffer, R.J.; Ant&, J.H. Med- 
ical O?zcology, Dana-Farber Cancer Institute, Boston, ]FLq. 
Sirolinms (Rapamune) is an immunosuppressive macrocyclic lac- 
tone similar in structure to tacrolimus and cyclosporine with a dis- 
tinct mechanism of action and toxicity profile. The drug has been 
used extensively in solid organ transplantation a d more recently, 
in stem cell transplantation. Methotrexate is a commonly used 
immunosuppressive agent that may paradoxically contribute to 
GVHD and transplantation-related toxicity indirectly through tis- 
sue damage. We tested the hypothesis that the synergistic combi- 
nation of sirolimus and tacrolimus would 1) result in effective 
GVHD prevention, 2) lead to rapid hematopoietic engraftment 
and 3) minimize transplant-related oxicity due to the omission of 
methotrexate. METHODS: To date, 9 patients have been treated 
with sirolimus (12 mg oral loading dose, 4 mg oral daily dose to 
maintain a level of 3-12 ng/ml) and tacrolimus (5-10 ng/ml serum 
level). All patients received cyclophosphamide (1800 mg/m2/day x 
2) followed by TBI (14 Cry in 7 fractions). Peripheral blood stem 
ceils from matched, related donors were infused on Day 0. Fil- 
grastim (5pg/kg) was administered from Day +12 until engraft- 
ment. RESULTS: The median patient age was 42 years (19-54) 
and 6/9 patients were male. Diagnoses included AML (6), NHL 
(2) and MDS (1). 6 patients had advanced isease. Oral sirolimus 
was well tolerated and therapeutic serum levels were attainable in 
all patients. All patients engrafted neutrophils at a median of 13 
days (range 12-I5) and platelets (> 20,000/gl) at a median of 13 
days (range 10-18). Grade 0-I acute GVHD occurred in 7/9 
patients. Grades II, III, and IV acute GVHD occurred in 2, 0 and 
0 patients respectively (total Grade II-IV GVHD 22%). The 
median time to first discharge was 20 days from transplantation 
(range 16-43). There was one case of non-fatal, severe VOD in a 
patient who had previously received Mylotarg. All patients remain 
alive at a median of 67 days, with one relapse in a patient with 
Burkitt's lymphoma. CONCLUSIONS:  The substitution of 
sirolimus for methotrexate is well tolerated and is associated with 
low regimen-related toxicity. There appears to be a reduction in 
the rate of acute GVHD using this synergistic ombination as 
well. This novel regimen is worthy of further study in allogeneic 
transplantation. We anticipate updated ata for presentation. 
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ACUTE RENAL FAILURE FOLLOWING NON-MYELOABLATIVE 
HEMATOPOIETIC STEM CELL TRANSPLANTATION - A MULTICEN- 
TER STUDY 
Parik,5, C.R.; McSweeney, P.; Schrier, R.W. U, iversi O, of Color,ado 
Health Scie,ces CeTzter, i)enve'r, CO. 
We have demonstrated that acute renal failure (ARF) is a con> 
mon life threatening complication following autologous and mye- 
loablative allogeneic hematopoietic stem cell transplantation 
(HSCT). The incidence of severe ARF, defined as doubling of 
serum creatinine, is 69% with myeloablative allogeneic HSCT. In 
this study 33% of the patients required dialysis and ARF occurred 
in the first 3 weeks after allogeneic HSCT. Non-myeloablative 
HSCT is a modification of conventional logeneic HSCT that is 
becoming a popular method ue to its safety and efficacy. It would 
be expected that severe ARF would be less with non-myeloablative 
HSCT, as the milder preconditioning re imen will cause less 
infections and less hypotension. The purpose of our study was to 
determine the course and severity of ARF associated with this pro- 
cedure. We analyzed the data collected on 286 patients who 
received non-myeloablative HSCT at 4 major university institu- 
tions (Fred Hutchinson Cancer Research Center, University of 
Colorado, Stanford University and City of Hope University). M1 
the patients who received non-myeloablative HSCT from 1998- 
2001 for hematological malignancy were included in the study. 
The patients were treated with multi-institutional shared proto- 
cols and thus preconditioning regimen and the post transplant 
imnmnosuppression were uniform. ARF was classified as mild 
(>25% increase in serum creatinine), severe (at least doubling of 
serum creatinine) and severe with dialysis. It was observed that the 
incidence of ARF is delayed and can be prolonged until 3 months 
after the non-myeloablative HSCT. The following table compares 
the risk of ARF from the non-myeloablative HSCT with the mye- 
loablative HSCT from our center. In summary, some degree of
ARf occured in 90% of the patients after non-myeloablative 
HSCT. The overall cumulative risk of developing severe ARF up 
to 3 months is 42 % with non-myeloablative patients. The require- 
ment of dialysis is ignificantly less in non-myelaoablative HSCT 
as compared to myeloabalative allogeneic HSCT (5% vs. 33%, 
P<0.01). In conclusion, although the patients receivcing the non- 
mycloablative transplant are older, the risk of developing renal 
failure and dialysis is ignificantly lower as compared to myeloab- 
lative HSCT. 
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LONG TERN COMPARISON OF RELAPSE AND OVERALL SURVIVAL 
IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AND 
ACUTE LYMPHOCYTIC LEUKEMIA (ALL) TREATED WITH UNRELAT- 
ED OR RELATED DONOR ALLOGENEIC MARROW/STEM CELL 
TRANSPLANTATION 
Al-Szdehz,1, S.Ad; Abel/a, Ed; /L~w~es, R.D.q Kara,es, C.:; Dmlsey, 
R.D. s 1. Hem./Olzc Division, Kmw~a,os Cmlcer i?zstitztte, DetJvit, MI; 
2. Nntio?lal Mmn'ow Donor Program, Mimzeapolis, MN. 
We have previously demonstrated no difference in surviwd for 
AML transplanted with either related (RD) or unrelated onors 
(URD) (:ASH 2001, abstract i719). This report extends our cxpe- 
rience comparing RD&URD transplants in patients with 
CML&ALL. Between August 1987 and June 2002, 120 patients 
with ALL and 213 patients with CML received alIogeneic trans- 
plants. 197 were males, and 136 were females with a mean age of 
32 years. 40 patients with ALL and 72 with CML received unre- 
lated donor marrow/stem cells, while the remaining patients 
received transplants ftom related onors. Pre-transplant ALL dis- 
ease status included CR1 in 29, >CR2 in 66, no remission in 22, 
and was unknown in 3 patients. Pre-transplant CML disease status 
included first chronic phase in 164, 2nd in 9, accelerated phase in 
25, blast crisis in 9, and unknown in 6 patients. Multiple condi 
tioning reghnens including busulphan (Bu) and cyclophosphamide 
(Cy), Cy / TBI, etoposide/TBI were used. GvHD prophyla~s was 
either cyclosporin or taerolimus with methotrexate or methyl- 
prednisolone. Overall, 154 (46%) are currently alive with 58 
(52%) deaths in the URD group and I21(55%) in the RD group 
and the longest survivor now at 11.4 years. The Kaplan-Meier dis- 
tribution of survival between URD & RD groups was not differ- 
ent by disease type (P = 0.57 for patients with ALL, P = 0.71 for 
patients with CML by the log rank test). This was true independ 
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